SAN DIEGO, March 31, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at The MicroCap Conference on Tuesday, April 4th, 2017, at 1:30 p.m. Eastern time (10:30 a.m. Pacific time). The conference is being held at The Essex House in New York City.
A live webcast of the corporate presentation will be available on the Company's website at ir.biocept.com. A replay of the presentations will be available for 90 days.
Biocept management will be available for one-on-one meetings with the investment community. Please contact David Moskowitz (email@example.com or 202-280-0888) if you would like to arrange a meeting during the conference. The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. More than 500 investors are expected to attend. For more information or to register to attend please visit http://microcapconf.com/conferences/new-york-2017/.
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-microcap-conference-on-april-4th-in-new-york-city-300432702.html
SOURCE Biocept, Inc.